Anzeige
Mehr »
Login
Sonntag, 05.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Cannabisaktien sollten nun den S&P um 60% outperformen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EJJQ | ISIN: FR001400JX97 | Ticker-Symbol: N/A
Lang & Schwarz
04.05.24
09:00 Uhr
0,396 Euro
0,000
0,00 %
1-Jahres-Chart  (nicht börsennotiert)
PIXIUM VISION SA Chart 1 Jahr
RealtimeGeldBriefZeit
0,3800,41204.05.
GlobeNewswire (Europe)
752 Leser
Artikel bewerten:
(2)

Pixium Vision announces the rejection of the sale plan (plan de cession) by the Court and the conversion of the receivership proceedings into liquidation proceedings

Pixium Vision announces the rejection of the sale plan (plan de cession) by the Court and the conversion of the receivership proceedings into liquidation proceedings

Paris, France, February 2, 2024 - 02:00 p.m. (CET) - Pixium Vision SA (Euronext Growth Paris - FR001400JX97; Mnemo: ALPIX), a bioelectronics company developing innovative vision systems to enable patients who have lost their sight to live more independent lives, announces the decision of the Paris Commercial Court, by a judgment of January 31, 2024, to reject the sale plan (plan de cession) presented by the company NeuroTech Vision, a wholly-owned subsidiary of NeuroTech Vision LLC, which is itself controlled by Priveterra Capital.

Pixium announces that the Paris Commercial Court has pronounced in a judgment of the same day, the conversion of the Company's receivership proceedings, opened by a judgment of November 13, 2023, into judicial liquidation proceedings.

Given the opening of judicial liquidation proceedings, there will be no resumption of the listing, and Euronext will soon proceed with the delisting of Pixium shares.

About Pixium Vision

Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision's bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The Company is EN ISO 13485 certified and qualifies as "Entreprise Innovante" by Bpifrance.

For more information: http://www.pixium-vision.com/fr

Follow us on @PixiumVision; www.facebook.com/pixiumvision

www.linkedin.com/company/pixium-vision

Contacts

Investor Relations

Pixium Vision
Offer Nonhoff
Chief Financial Officer
investors@pixium-vision.com (mailto:investors@pixium-vision.com)

Media Relations

Rose Piquante Consulting
Sophie Baumont
Sophie.baumont@rosepiquante-consulting.com
+33 6 27 74 74 49

Attachment

  • Pixium - Conversion into liquidation proceedings - 01.02.2024 (https://ml-eu.globenewswire.com/Resource/Download/f90cf987-462e-4511-8465-865ba69fad8c)

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2024 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.